
Triaging Your QMS: Considerations Based on the New QMSR
Apr 17, 2026 - 59:19
Radio and PodcastLive Radio & Podcasts
In this Medtech Matters podcast episode of Mike on Medtech with Mike Drues, president of Vascular Sciences , we’re highlighting comments made by FDA representatives at an event about the most common premarket review issu...
3 Most Common Premarket (Postmarket?) Review Issues FDA Sees is an episode from Medtech Matters by Medical Product Outsourcing. In this Medtech Matters podcast episode of Mike on Medtech with Mike Drues, president of Vascular Sciences , we’...
This episode belongs to Medtech Matters.
Use the player on this page to stream the episode online.
Published Jun 25, 2025, 53:16 long, audio available.
In this Medtech Matters podcast episode of Mike on Medtech with Mike Drues, president of Vascular Sciences , we’re highlighting comments made by FDA representatives at an event about the most common premarket review issues they see in submissions. First, there is some discussion regarding whether the issues are truly premarket or postmarket concerns. Then, we look at what these are, why they are likely so common, examples of them, and how to avoid running into these issues yourself. During this conversation, the following questions are addressed: Recently, three medical device senior operations officers from FDA’s Office of Inspections and Investigations spoke at a conference about the most common “issues” FDA encounters during the premarketing review of medical devices. Can you give a recap of what they said? In your 30+ years of experience working in the medical device industry, would you agree with FDA that these are the three most common issues? Before discussing the three specific common problems individually, what do you think is the “root cause” of these problems? Can you provide some examples? How can design change and design creep get companies in trouble with FDA? What does “marketing beyond authorized intended use” mean? Do you have suggestions and/or best practices to avoid running into problems around these issues? What else is important? What are today’s takeaways? Listen to this discussion and see if you've run into these issues yourself. If you’d like to share thoughts, ask questions, or have a suggestion for a future topic for us to cover, please reach out to me at sfenske@rodmanmedia.com and Send us Fan Mail For more medtech news and information, visit
You can listen to 3 Most Common Premarket (Postmarket?) Review Issues FDA Sees online on Radio and Podcast. Open the player on this page to stream the available audio.
3 Most Common Premarket (Postmarket?) Review Issues FDA Sees is an episode from Medtech Matters by Medical Product Outsourcing.
This episode is 53:16 long.
This episode was published on Jun 25, 2025.
Yes. Use the heart button on the episode page to add it to your favorite episodes list.
Yes. This page shows related episodes from Medtech Matters when more episodes are available from the podcast feed.
You can listen to 3 Most Common Premarket (Postmarket?) Review Issues FDA Sees on this page when the episode audio is available from the podcast feed.
3 Most Common Premarket (Postmarket?) Review Issues FDA Sees is from Medtech Matters by Medical Product Outsourcing.
Published Jun 25, 2025 and 53:16 long